Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Hemostemix Inc. (V:HEM)

Business Focus: Bio Therapeutic Drugs

Mar 07, 2024 04:01 pm ET
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice related to the Company's capital markets strategy. Services include advice on the structure of equity or debt capital financing and the identification of potential future investors.
Feb 06, 2024 10:08 am ET
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results today.
Dec 29, 2023 04:02 pm ET
Hemostemix Clarifies its October 3, 2023 News Release
Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October 3, 2023. It refered to the private placement of $320,125. The Company closed the financing in the amount of $320,385 with the issuance of 2,669,875 units. In connection with that Offering, the Corporation paid eligible finders aggregate fees of $5,750.40 in cash and issued 47,920 finder options to purchase common shares of the Corporation, at an exercise price of $0.12 per common share within 24 months from the closing of the Offering.
Oct 30, 2023 02:16 pm ET
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Calgary, Alberta--(Newsfile Corp. - October 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company's seventh peer reviewed study of ACP-01 - the third peer reviewed study of ACP-01 as a treatment for heart disease (ischemic and non-ischemic dilated cardiomyopathy), which demonstrates ACP-01 regenerates and improves cardiac function by up to 24.1% at 12 months in ischemic cardiomyopathy, and regenerates and improves cardiac function in non-ischemic cardiomyopathy patients by up to 47.1% at 12 months (dLVEF%/iLVEF%).
Oct 23, 2023 10:03 am ET
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
Calgary, Alberta--(Newsfile Corp. - October 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which originally closed on June 11, 2021 ("CD1") resulting in an expected interest saving of $569,868.
Oct 03, 2023 10:55 am ET
Hemostemix Closed $320,125 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately 2.66 Million Units priced at $0.12 each. Each Unit sold consisted of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Sep 27, 2023 05:10 pm ET
Hemostemix Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - September 27, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately 2.7 Million Units priced at $0.12 each. Each Unit shall consist of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Sep 12, 2023 09:15 am ET
Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces
Calgary, Alberta--(Newsfile Corp. - September 12, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication. Mitigating Challenges Facing Clinical Applications of Implantable Biosensors Supporting Brain Computer Interfaces is co-authored by Dr. Chris McNorgan, Dr. Fraser C. Henderson, Sr., Dr. Ina Sarel, Dr. Ken Webb and Dr. Jeong Soo Lee.
Aug 29, 2023 01:58 pm ET
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant funding of $6 Million, to locate production of ACP-01 in Montreal.
Aug 14, 2023 09:06 am ET
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement
Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that on August 10, 2023 it received a final cost award from the International Center for Dispute Resolution (ICDR), International Abritration Tribunal, in the Matter of Arbitration between Elmar Burchardt vs Hemostemix Inc. The award stipulates Dr. Burchardt is to pay Hemostemix Inc. CAD $315,684 of its costs. Certified, for the purposes of Article I of the New York Convention of 1958 on the Recognition and Enforcement of Foreign Arbitral Awards, the Final Award was made in Calgary, Alberta, Canada.
Aug 08, 2023 11:45 am ET
Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review
Calgary, Alberta--(Newsfile Corp. - August 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it submitted for publication its retrospective cardiomyopathy study to a leading stem cell journal. The study, Safety and Outcomes Analysis: Transcatheter Implantation of Autologous Angiogenic Cell Precursors for Treatment of Cardiomyopathy, was co-authored by Jane R. Schubart PhD, Amirhossein Zare MD, Roberto M. Fernandez-de-Castro MD, MSc, Hector Rosario Figueroa MD, Ina Sarel PhD, Kelly Tuchman RN, Kaitlyn Esposito MPH, Fraser C. Henderson Sr MD, Ernst von Schwarz MD, PhD.
Jun 28, 2023 08:56 am ET
Hemostemix Closes $403,539 of the Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - June 28, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price of $0.12 per Unit for gross proceeds of $403,539.96. In connection with the Closing, the Corporation will pay finder fees ("Finder Fees") to one or more advisors, dealers or finders ("Finders") for their assistance in the Private Placement including: (a) a Finder's fee payable in cash not to exceed 8% of the aggregate gross proceeds, equal to $19,803.19; and (b) issuing 165,027 finder options ("Finder Warrants") exercisable for a period of 24 months from the closing date of the Private Placement, to acquire Common Shares at a price of $0.12 per Common Share.
Jun 21, 2023 04:52 pm ET
Hemostemix's Private Placement Use of Proceeds
Calgary, Alberta--(Newsfile Corp. - June 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce the gross proceeds from the non-brokered private placement are to commence the buildout of production of ACP-01 via a contract in the form of a production facility cotenancy agreement negotiated by the Issuer, pay current filing, regulatory, and finder fees in connection with the offering, and for general working capital purposes.
Jun 01, 2023 08:58 pm ET
Hemostemix Announces Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 10 Million Units priced at $0.12 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
May 03, 2023 12:44 am ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, May 2, 2023 /CNW/ -
May 02, 2023 11:24 am ET
IIROC Trading Resumption - HEM
VANCOUVER, BC, May 2, 2023 /CNW/ - Trading resumes in:
May 02, 2023 10:35 am ET
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
Calgary, Alberta--(Newsfile Corp. - May 2, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Chris McNorgan, PhD, to drive a license agreement of NCP-01 with a company who is pursuing neural electrode-based brain intervention. Dr. McNorgan's research - the neural bases of cognition, including AI methods to decode and simulate neocortical representations of knowledge and motor intention - is directly relatable to neural electrode-based implantation.
May 02, 2023 09:31 am ET
IIROC Trading Halt - HEM
VANCOUVER, BC, May 2, 2023 /CNW/ - The following issues have been halted by IIROC:
Apr 03, 2023 09:21 am ET
Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates
Calgary, Alberta--(Newsfile Corp. - April 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is completing a second round of interviews with candidates who may join the company as Executive Vice President, Business Development. The EVP Business Development will be responsible for building and leading a team focused on the following:
Mar 29, 2023 12:45 pm ET
Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
Calgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Montreal's RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia "CLI" and peripheral arterial disease "PAD" patients, globally. The purpose of the revisions are to engage with CLI and PAD patients, to provide them with ACP-01 as limb saving treatment, and to provide them with strategies that may improve their quality of life. For example, when an individual seeks a solution to PAD or CLI, the Hemostemix site will be the first website that they obtain. Within the CLI landing page, it will contain the following information:
Mar 21, 2023 01:55 pm ET
Hemostemix Closes $762,400 of The Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it has closed its first tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of $762,400 (the "Offering"). The Offering consisted of the issuance of an aggregate of 3,812,000 Units at a price of $0.20 per Unit.
Mar 08, 2023 03:02 pm ET
Hemostemix Unit Offering Repriced
Calgary, Alberta--(Newsfile Corp. - March 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announces it is repricing its offering of 14 Million Common Share Units to $0.20 each. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.65 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Mar 07, 2023 09:00 am ET
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval
Calgary, Alberta--(Newsfile Corp. - March 7, 2023) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("HEM" or the "Company") is pleased to announce it is selling up to 500 five-year 6% unsecured convertible debentures ("CD") at USD $35,000 each. The CD can be converted into one of 500 ACP-01 therapeutic production slots ("TPS"), subject to patients' compassionate exemption from regulatory approval, or is convertible into Common Shares of Hemostemix as described below.
Feb 01, 2023 08:31 pm ET
Hemostemix Announces Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - February 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 14 Million Units priced at $0.24 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.65 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Jan 31, 2023 09:26 am ET
The Force Family Office Engaged by Hemostemix
Calgary, Alberta--(Newsfile Corp. - January 31, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is plugged into the largest network of family offices in the United States via its agreement with the Force Family Office. In 2022, The Force Family Office hosted more than 150 events, connecting family offices with private and public companies for co-investment. Founded in 2020 by Steven Saltzstein with a singular focus to create a forum where family offices from across the world could learn about emerging companies, Force has grown to include to include 200,000 representatives of family offices.
Jan 30, 2023 03:50 pm ET
Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland
Calgary, Alberta--(Newsfile Corp. - January 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its Trademark, Your Fountain of Youth, was granted protection in Switzerland by its Trademark Office. Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., has received a Statement of Grant of Protection from the Swiss Trademark Office, and notice of the grant from the World Intellectual Property Organization.
Jan 26, 2023 03:27 pm ET
Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office
Calgary, Alberta--(Newsfile Corp. - January 26, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth.
Jan 24, 2023 09:00 am ET
Hemostemix Wins Arbitration Decision
Calgary, Alberta--(Newsfile Corp. - January 24, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Arbitrator has dismissed Dr. Burchardt's claims for compensation and damages against the Company, set aside the Change of Control Agreement on the grounds that it was entered into in violation of Dr. Burchardt's duties as a director under sections 120 and 122 of the Business Corporations Act (Alberta), and determined that he lacked jurisdiction to consider the Burchardt stock option claims, and tort claims for defamation and interference with economic relations.
Jan 24, 2023 06:00 am ET
InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal and Applying for Grants to Fund Up to 75% of 5-Year Expenses
Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0), an autologous stem cell therapy company, is hiring four biotechnologists to re-establish the company’s production of ACP-01 in Montreal. This staffing requirement arose because of the recently...
Jan 23, 2023 09:37 am ET
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is hiring four new biotechnologists to re-establish the Company's production of ACP-01 in Montreal. The Company is hiring an experienced autologous stem cell therapy Manufacturing Manager, a Quality Control Manager, and two Manufacturing Technologists. Coincidentally, Hemostemix has applied for Federal and Provincial grant funding that may cover up to 75% of its capital and operating expenses to build and operate its cGMP facility during its first five years of operation.
Jan 23, 2023 06:00 am ET
InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01
Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. Under the Letter of Commitment, the MUHC...
Jan 19, 2023 11:28 am ET
Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation
Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. The Letter of Commitment confirms that the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy at the McGill University Health Centre (MUHC).
Jan 19, 2023 10:41 am ET
IIROC Trading Resumption - HEM
VANCOUVER, BC, Jan. 19, 2023 /CNW/ - Trading resumes in:
Jan 19, 2023 09:10 am ET
IIROC Trading Halt - HEM
VANCOUVER, BC, Jan. 19, 2023 /CNW/ - The following issues have been halted by IIROC:
Dec 08, 2022 02:34 pm ET
Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus
Calgary, Alberta--(Newsfile Corp. - December 8, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Office of the Registrar of Trademarks, Republic of Cyprus, issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. The Trademark is registered initially for 10 years. The Company's has a right to renew for additional 10-year periods by application.
Nov 30, 2022 10:02 am ET
Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") thanks Mr. Neim Malo, founder of Beefstro's, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s).
Nov 17, 2022 08:29 am ET
Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0) now available on YouTube.
Nov 15, 2022 08:43 am ET
Hemostemix Announces Advancements in Its Automation of Production
Calgary, Alberta--(Newsfile Corp. - November 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale our autologous stem cell therapy processes by leveraging robotic-material-handling and parallel-processing efficiencies, duplicating our manual methods of angiogenic cell precursor (ACP-01) production. ACTS will scale ACP-01 production to generate the highest quality, safest and efficacious patient derived stem cell therapeutic.
Oct 26, 2022 10:39 am ET
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr. Giannetti and Dr. Cecere will assist Hemostemix with financing introductions and due diligence responses; help position ACP-01 as a candidate to be the first-to-patient autologous stem cell treatment of heart disease; design the Company's fourth heart-focused clinical trial; and, assist management with the re-establishment of ACP-01 production.
Oct 25, 2022 11:36 am ET
Hemostemix Announces Presentation to the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") invites shareholders, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference on Wednesday, October 26th at 12:00 EDT. Attendees may use the following link to attend:
Oct 19, 2022 09:43 am ET
Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
Calgary, Alberta--(Newsfile Corp. - October 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") and its wholly-owned subsidiary, PreCerv Inc., are pleased to announce the commencement of PreCerv Inc.'s study of NCP-01.
Oct 04, 2022 09:00 am ET
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Financing Alternatives"), after retaining experts in the field of biotech business development who have significant experience completing deals on behalf of pharmaceutical companies with promising companies like Hemostemix.
Sep 27, 2022 09:00 am ET
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board.
Sep 20, 2022 08:45 am ET
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board.
Sep 16, 2022 10:32 am ET
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 16, 2022) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board.
Sep 15, 2022 11:14 am ET
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Johannes Grillari to its Scientific Advisory Board.
Sep 14, 2022 01:02 pm ET
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board.
Sep 14, 2022 10:26 am ET
Hemostemix Announces Its Presentation to the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") invites individuals, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference at 12:00 ET today https://goto.webcasts.com/starthere.jsp?ei=1552113&tp_key=93e040bf55&sti=hmtfx.
Sep 13, 2022 09:00 am ET
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc.
Aug 31, 2022 01:27 pm ET
Hemostemix Announces A Clarification
Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") received numerous enquiries about the press release of August 30, 2022. This press release details the results in a table format and clarifies a misprint.
Aug 30, 2022 09:00 am ET
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the results of its Phase II Clinical Trial and the results of a new retrospective study of patients that underwent a trans-catheter, intramyocardial injection of angiogenic cell precursors (ACP-01) as a treatment for heart failure (ischemic and non-ischemic dilated cardiomyopathy).
Aug 22, 2022 04:50 pm ET
Hemostemix Announces Closing of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - August 22, 2022) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a tranche of its previously announced non-brokered private placement of units ("Units") as announced on August 19, 2022 for gross proceeds of $192,000 (the "Offering"). The Offering consisted of the issuance of an aggregate of 640,000 Units at a price of $0.30 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Aug 19, 2022 11:34 am ET
Hemostemix Announces Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - August 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to five Million Units priced at $0.30 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Aug 12, 2022 08:55 am ET
Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - August 12, 2022) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a second tranche of its previously announced non-brokered private placement of units ("Units") as announced on May 19, 2022 for gross proceeds of $1,364,710.10 (the "Offering"). The Offering consisted of the issuance of an aggregate of 4,549,034 Units at a price of $0.30 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Jun 22, 2022 04:02 pm ET
Hemostemix Announces Closing of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - June 22, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it closed the first tranche of its non-brokered private placement of units ("Units") announced on May 19, 2022, for gross proceeds of $690,388.80 (the "Offering"). The Offering consisted of the issuance of an aggregate of 2,301,296 Units at a price of $0.30 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Jun 14, 2022 08:21 am ET
Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01
Calgary, Alberta--(Newsfile Corp. - June 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has incorporated PreCerv Inc. ("PreCerv"), as a wholly owned subsidiary. PreCerv will obtain from Hemostemix a global field of use license to NCP-01 and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system, including but not limited to the following:
May 19, 2022 04:55 pm ET
Hemostemix Announces Financing
Calgary, Alberta--(Newsfile Corp. - May 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to 15 Million Units priced in the context of the market. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
May 19, 2022 11:29 am ET
Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations
Calgary, Alberta--(Newsfile Corp. - May 19, 2022) -   Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Peter Pavlin, P.Eng. to the position of Vice President Operations.
May 16, 2022 09:49 am ET
Hemostemix Announces Rick Groome as Special Advisor to The CEO
Calgary, Alberta--(Newsfile Corp. - May 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce Mr. Richard ("Rick") Groome has joined Hemostemix as a special advisor to the CEO, focused on completing a series of financing transactions. Over the last three decades Mr. Groome was instrumental in creating and building two securities firms, Marleau Lemire and Groome Capital, which funded many successful biotechnology companies.
May 10, 2022 09:00 am ET
Hemostemix Announces Its Intellectual Property is Back Home
Calgary, Alberta--(Newsfile Corp. - May 10, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has settled all litigation with, and closed the settlement agreement with, Aspire Health Services, Inc., AJIA Global, LLC and Alan Jacobs, Jed Wood, Randi Wood, Blake Wood, Kyle Makofka, Reginald Cooper, and Kingsman Scientific Management. Hemostemix is now in possession of all of its intellectual property, including all HS 12-01 Phase II clinical trail data, all historical data from Hemostemix Israel, and the randomization tables that are required to analyse the North American and South African ACP-01 clinical trial data.
Apr 25, 2022 09:00 am ET
Hemostemix Announces Closing of $2,750,000
Calgary, Alberta--(Newsfile Corp. - April 25, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it has closed its previously announced $2,750,000 non-brokered secured convertible debenture unit offering (the "Debenture Offering"), pursuant to which the Company issued 2,750 debenture units (each a "Debenture Unit") at a price of $1,000 per Debenture Unit.
Apr 12, 2022 08:18 am ET
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
Calgary, Alberta--(Newsfile Corp. - April 12, 2022) - Hemostemix Inc.  (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that, further to its March 23, 2022 news release, Hemostemix has completed the audit of its ACP-01 clinical trial data and intellectual property held by Aspire Health Sciences, LLC ("Aspire") and Accudata Solutions, Inc. ("Accudata"), and Hemostemix has confirmed the materials held by Aspire and Accudata are complete and appear to be free of manipulation in any way. If and when the closing of the Settlement Agreement occurs, Hemostemix shall pay Aspire a confidential monetary sum for termination of the license agreement and for providing Hemostemix with all clinical trial data and intellectual property of the Company held by Aspire and other signatories of the Settlement Agreement. While the closing of the Settlement Agreement is subject to several conditions and ‎‎contingencies, and there can be no assurance that the closing of the Settlement Agreement will be ‎completed, ‎the Parties are contracted to close this transaction in the next 30 to 60 days. Hemostemix's inspection of the materials held by Aspire confirms the underlying disputes were business disputes among the parties and there was no harm to Hemostemix's intellectual property. This settlement resolves these business disputes, and upon closing of the Settlement Agreement, all three lawsuits will be dismissed with prejudice.
Mar 23, 2022 03:28 pm ET
Hemostemix Announces Settlement Agreement
Calgary, Alberta--(Newsfile Corp. - March 23, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has entered into a settlement agreement (the "Settlement Agreement") with Aspire Health Science, LLC ("Aspire"), and certain other persons, to settle all pending litigation with Aspire, and certain other persons, including in respect of the Delaware Federal Action, the Florida State Action and the Florida Federal Action involving those persons. If and when closing of the Settlement Agreement occurs, Aspire, and other signatories to the Settlement Agreement, are required to return all data and intellectual property in relation to ACP-01 in their possession (the "ACP-01 Data") to Hemostemix. The Settlement Agreement also calls for the performance of a data audit by Hemostemix in relation to the ACP-01 Data in order to review the ACP-01 Data to be returned to Hemostemix (the "Data Audit"), which Data Audit is currently underway.
Mar 03, 2022 09:00 am ET
Hemostemix: Interest Payment on Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - March 3, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021. Please refer to the Company's new release dated June 21, 2021 for details of the terms and conditions of the convertible debenture.
Mar 02, 2022 09:15 am ET
Hemostemix Announces $2,750,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - March 2, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has signed a binding term sheet for a private placement of convertible debentures in the amount of $2,549,000, and is offering the same terms to accredited investors who are shareholders of record of March 3, 2022, enabling the Company to accept or reject in its sole discretion, proceeds of up to $2,750,000. The use of proceeds is for general working capital purposes.
Mar 01, 2022 10:00 am ET
Hemostemix Announces Stock Options Grant
Calgary, Alberta--(Newsfile Corp. - March 1, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of ‎Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 1,194,269 vest immediately and 300,000 vest 50% immediately and 50% on February 28, 2023. All options were granted with an exercise price of $0.17 per common share and have an expiry date of February 28, 2027. After ‎this Option issuance, Hemostemix has 6,836,269 Options issued and outstanding. Of the Options granted, 793,050 Options were issued to directors and officers of Hemostemix. Hemostemix relied on section 5.5(b) of Multilateral Instrument 61-101 - Protection of Minority ‎Security Holders in ‎Special Transactions ‎‎("MI 61-‎‎101")‎ as the exemption from the formal ‎‎valuation ‎requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 in respect of the ‎Options grant to the directors and ‎officers of Hemostemix as no securities of ‎Hemostemix are listed on a ‎specified market as defined in MI 61-101. Hemostemix relied on section ‎‎5.7(a) of MI 61-101 as the exemption from ‎the minority approval ‎requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 ‎in ‎respect ‎of the Options grant to the directors and officers of Hemostemix as neither the fair ‎‎market value of the subject matter of, nor the fair market value ‎of the consideration for, the Options granted to the directors and officers of the Company exceeded 25% of Hemostemix's ‎‎market capitalization.‎‎ The Compensation Committee and Board of Directors of the Company have approved the Options grant and no materially contrary view or ‎abstention ‎was expressed or made by any director in relation to the Options grant.‎ The material change report to be filed in relation to the Options grant will not be not filed at ‎least 21 days prior to the completion of the Options grant as ‎contemplated by MI ‎‎61-101. The Company believes that this shorter period is reasonable and ‎necessary in the ‎circumstances as the completion of the Options grant occurred shortly before the ‎issuance of this news release and the filing of such material change report.‎
Feb 28, 2022 08:41 pm ET
Hemostemix Announces Closing of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - February 28, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") announces that it has closed its previously announced non-brokered private placement of units ("Units") announced on February 2, 2022, for gross proceeds of $1,204,849.92 (the "Offering"). The Offering consisted of the issuance of an aggregate of 8,606,071 Units at a price of $0.14 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.40 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Feb 14, 2022 09:10 am ET
Your Fountain of Youth Trademarked by Hemostemix
Calgary, Alberta--(Newsfile Corp. - February 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce "Your Fountain of Youth" has been trademarked by the Company's intellectual property holding company, Kwalata Trading Limited. Hemostemix has been granted International Trademark Registration No. 1624069 for Your Fountain of Youth, a registration that is valid for a period of 10 years. In receipt of notices from both the World Intellectual Property Organization and the European Union Intellectual Property Office, the registration has been sent by the International Bureau to the offices of 107 designated countries who are each a signatory to the Madrid Agreement.
Feb 02, 2022 09:54 am ET
Hemostemix Announces Financing
Calgary, Alberta--(Newsfile Corp. - February 2, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to 7,200,000 Units at $0.14 each for gross proceeds of up to $1,008,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 7,200,000 Units at a price of $0.14 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.40 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Jan 21, 2022 09:36 am ET
Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics
Calgary, Alberta--(Newsfile Corp. - January 21, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a Global Master Services Agreement with My Next Health ("MNH"), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit.
Jan 11, 2022 09:44 am ET
Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes
Calgary, Alberta--(Newsfile Corp. - January 11, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a contract with Dr. James Shapiro, University of Alberta, Edmonton and will complete a transfer ACP-01 to Dr. Shapiro's laboratory. The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis in the heart and limbs of individuals who suffer from ischemia, and cell transplants from human islets or stem cells, hold huge promise in the treatment of diabetes. Following technology transfer, the team will create a new product by combining the two formulations, beginning with human islets. Thereafter, the team will complete preclinical studies to demonstrate the product's characteristics in vivo, with a plan to move forward with first-in-human testing.
Dec 14, 2021 07:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com
Dec 09, 2021 11:19 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.
Dec 09, 2021 10:54 am ET
Hemostemix Announces Soft Lock of Database as Source Document Verification Completed
Calgary, Alberta--(Newsfile Corp. - December 9, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB :HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal investigators, the HS 12-01 database will be locked.
Oct 28, 2021 09:29 am ET
Hemostemix Confirms OTCQB Listing
Calgary, Alberta--(Newsfile Corp. - October 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it is now up-listed to trade on the OTCQB under symbol HMTXF. The common shares of Hemostemix will continue to trade on the Frankfurt Stock Exchange under the symbol "2VFO" and trade on the TSX Venture Exchange under the symbol "HEM".
Oct 19, 2021 12:06 pm ET
Hemostemix Confirms OTCQB Application is Filed
Calgary, Alberta--(Newsfile Corp. - October 19, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it filed with the compliance department of OTCQB all documentation required to up-list the Company's common shares on the OTCQB. The Company's application is under review. The common shares of Hemostemix will continue to trade on the Borse Frankfurt under the symbol "2VFO" and trade on the TSX Venture Exchange under the symbol "HEM".
Oct 14, 2021 09:15 am ET
Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
Calgary, Alberta--(Newsfile Corp. - October 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer.
Oct 04, 2021 02:05 pm ET
Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain
Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the second in its series of video interviews with ACP-01 recipients taped during August of 2021. With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this one-minute segment Peter recounts how his chest pain dissipated one week after his stem cell treatment, and he recounts how he felt like his life was back to normal after six weeks. Interested parties are directed to the Video and ACP Testimonials section of the Company's website (https://hemostemix.com/acp-testimonials/).
Sep 21, 2021 09:21 am ET
Hemostemix Announces Closing of First Tranche of Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - September 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed a first tranche of its previously announced non-brokered private placement of units ("Units") announced on September 8, 2021, for gross proceeds of $373,500 (the "Offering"). The Offering consisted of the issuance of an aggregate of 1,494,000 Units at a price of $0.25 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Sep 14, 2021 09:10 am ET
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Calgary, Alberta--(Newsfile Corp. - September 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the first of a series of video interviews with ACP-01 recipient-patients taped during August of 2021. Treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, chronic obstructive pulmonary disease and vascular dementia, each recipient of the ACP-01 treatment recounts in full detail their return to a quality of life they thought was lost forever. In the first three-minute segment, this five-time Grammy Award Winner, Howie Lindeman, recounts how his ejection fraction improved nearly 100%, increasing to 40 from the low 20s.
Sep 08, 2021 04:54 pm ET
Hemostemix Announces Five Million Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - September 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement for gross proceeds of up to $1,250,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 5,000,000 units ("Units") at a price of $0.25 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Jul 06, 2021 06:22 pm ET
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Calgary, Alberta--(Newsfile Corp. - July 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to provide an update on the Phase II Clinical Trial, an update of a decision including a cost award from the Ninth Judicial Circuit Court of Orange County, Florida, and the Annual General Meeting ("AGM") results.
Jul 05, 2021 06:25 pm ET
Hemostemix Announces Warrant Repricing and Extension
Calgary, Alberta--(Newsfile Corp. - July 5, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce, subject to TSX Venture Exchange Approval, that it has extended for two years and repriced to $0.55 from $1, subject to the accelerator provisions stated below on all repriced warrants, 1,332,500 Warrants expiring July 9, 2021; extended 918,450 Warrants expiring November 24, 2021 of which 510,295 Warrants are repriced to $0.55 (408,155 Warrants held by insiders not repriced from $1); extended 6,360,585 Warrants expiring December 18, 2021, repricing 4,733,559 Warrants (1,627,026 Warrants held by insiders are not repriced from $1); extended 9,166,667 Warrants expiring December 31, 2021, repricing 8,513,334 Warrants (653,333 Warrants held by insiders not repriced from $1).
Jun 21, 2021 10:01 pm ET
Peter Lacey Increases His Investment in Hemostemix Inc.
Calgary, Alberta--(Newsfile Corp. - June 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") announced today that, further to its June 11, 2021 news release and pursuant to the closing of the offering of debenture units of the Company ("Debenture Units"), Peter Lacey, a director and Chair of Hemostemix, acquired the 2,500 Debenture Units. Each Debenture Unit consisted of a $1,000 principal amount debenture (each, a "Debenture") and 2,500 common share purchase warrants ("Debenture Warrants"). The ‎principal amount of the Debentures may be convertible, only at the option of the Company (and not at the option of ‎the holder), into common shares of the Company ("Common Shares") of the at a price of $0.40 per Common Share. Each Debenture Warrant entitles the holder to acquire one Common Share at a price of $0.55 per Common Share until June 10, 2023, subject to accelerated expiry provisions. Prior to the offering, Mr. Lacey held ‎4,491,891‎ Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares. Mr. Lacey also held 4,500,000 common share purchase warrants and 555,000 stock options. Mr. Lacey now controls ‎ ‎4,491,891‎ Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares, the Debenture in the principal amount of $2,500,000, ‎10,750,000 common share purchase warrants (including the Debenture Warrants) and 555,000 stock options. Assuming the conversion of the Debenture and the exercise of the common share purchase warrants (including the Debenture Warrants) and the stock options, Mr. Lacey would own or control ‎22,046,891 Common Shares, or approximately 29.35% of the total issued and outstanding Common Shares. The acquisition of ‎the Debenture Units by Mr. Lacey was made for investment purposes. Mr. Lacey may increase or ‎decrease his investment in Hemostemix depending on market conditions or any ‎other relevant factors. The ‎head office address for Hemostemix is Suite 1150, 707 - 7th Avenue SW, Calgary, Alberta T2P 3H6. The address for Mr. Lacey is 38501 Range ‎Road 272‎, Red Deer, Alberta T4P 0X6. ‎
Jun 11, 2021 08:10 am ET
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 11, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it closed its previously announced $2,500,000 convertible debenture order from a director of the Company for Debenture Units priced at $1,000 per Unit as detailed below.
May 31, 2021 10:38 am ET
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Share
Calgary, Alberta--(Newsfile Corp. - May 31, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) ‎‎(FSE:2VF0) ("Hemostemix" or the "Company") reminds shareholders that due to COVID-19, its Annual and Special Meeting will be held by Zoom only.
May 29, 2021 03:56 pm ET
Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update
Calgary, Alberta--(Newsfile Corp. - May 29, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce that it has obtained preliminary approval from the TSX Venture Exchange to close a $2,500,000 convertible debenture order from a director for Debenture Units priced at $0.40 per Unit as detailed below. On May 28, 2021, Hemostemix filed its Financial Statements and Management Discussion and Analysis for the period ending March 31, 2020 on SEDAR.
May 25, 2021 11:39 am ET
Hemostemix to Present at the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - May 25, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce that it will present live at the Emerging Growth Conference on May 26, 2021 from 3:30 - 4:00 ET and it invites shareholders, individual and institutional investors, as well as advisors and analysts to attend its real-time, interactive presentation.
May 10, 2021 10:16 pm ET
Hemostemix Announces Closing of Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - May 10, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") announced on April 9, 2021, for gross proceeds of $440,031.90 (the "Offering"). The Offering consisted of the issuance of an aggregate of 1,257,234 Units at a price of $0.35 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one transferable common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.40 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
May 06, 2021 08:38 pm ET
Hemostemix Announces Warrant Repricing and Extension
Calgary, Alberta--(Newsfile Corp. - May 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading days during the unexpired term of the Warrants, the weighted average closing price of the Company's listed shares achieves or exceeds the price of 120% of the applicable exercise price ($0.66). The 30-day expiry period commences on the day the Company either (i) disseminates a press release, or (ii) sends a written notice to the holders of the Warrants advising of the commencement of the exercise period.
Apr 30, 2021 10:22 pm ET
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
Calgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up completed in April, the Company is now focusing its efforts on completing the key areas of the trial including, but not limited to, data entry, source document verification, data base query management and validation as more fully described below, biostatistical analyses and final reporting documentation. This process is expected to take approximately three months.
Apr 26, 2021 09:00 am ET
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 26, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company") announces that, further to its April 9, 2021 news release announcing its Unit Offering, it has increased the aggregate gross proceeds of its Unit Offering to $1,050,000, reduced the Unit price to $0.35 per Unit, and reduced the exercise price of the Warrants to $0.40 per Common Share. In addition, further to its April 9, 2021 news release announcing its Debenture Offering, Hemostemix announces that it has decreased the Conversion Price of its Debenture Offering to $0.40 per Common Share and increased the amount of Common Share purchase warrants ("Debenture Warrants") granted as part of the Debenture Units to 2,500 Debenture ‎Warrants per each Debenture Unit. The exercise price of the Debenture Warrants issued as part of the Debenture Units remains at $0.55 per Common Share. The remainder of the terms of the Offerings announced on April 9, 2021 remain the same. The full details of the amended Offerings are set forth below.
Apr 23, 2021 03:00 pm ET
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. The entry of all subjects' information into the clinical trial data base and source document verification processes are ongoing and this is a crucial preliminary step in finalizing the Phase II Clinical Trial.
Apr 09, 2021 08:56 pm ET
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
Calgary, Alberta--(Newsfile Corp. - April 9, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has secured a $2,500,000 lead order from a director for Debenture Units, and intends to raise gross proceeds of up to $4,000,000 from the non-brokered Offerings of Units and Debenture Units, all as discussed below. The Company is progressing with completion of the phase II clinical trial data entry, source document ‎verification, and statistical analyses. ‎The United States District Court for the District of Delaware has ruled Hemostemix's claims against Aspire ‎and Accudata, except Count VII (fraud), are permitted to proceed (motions to stay and motions to dismiss denied) and the Company's preliminary injunction application was also denied. Accudata and Aspire must now answer the amended complaint by Monday, April 12, 2021.
Apr 08, 2021 08:55 am ET
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
Calgary, Alberta--(Newsfile Corp. - April 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0.F) ("Hemostemix" or the "Company") is pleased to announce it is trading on the Frankfurt Stock Exchange under symbol 2VF0.F and it has engaged HE Capital Markets Ltd. (HE Capital) to design and implement a North American and European multimedia digital advertising campaign on certain investor-focused and financial market websites. HE Capital will also provide other media communications services to raise the company's overall corporate profile in North America and Europe.
Mar 18, 2021 09:22 am ET
Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities
Calgary, Alberta--(Newsfile Corp. - March 18, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that it has contracted two additional clinical research associates, is completing the remaining data entry and source document verifications, and has subscribed with GlobeX Data Ltd. (OTCQB: SWISF) (CSE: SWIS) (FSE: GDT), to encrypt its email communications with regulatory authorities in a secure portal.
Feb 11, 2021 09:15 am ET
Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
Calgary, Alberta--(Newsfile Corp. - February 11, 2021) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM; OTC: HMTXF) is pleased to announce it has contracted Protocol First to provide it with source document verification services. Protocol First's P1 Source Upload solution, which runs alongside any EDC system, allows site coordinators to upload un-redacted source data at the click of a button. The CRA/monitor can remote monitor the data, mark it as reviewed, issue queries to the site, and create reports for management, all within an FDA approved solution.
Jan 28, 2021 09:23 am ET
Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced
Calgary, Alberta--(Newsfile Corp. - January 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that all follow-up visits of the subjects enrolled in the HS 12 -01 clinical trial will be completed by March 31, 2021. A total 65 subjects who were enrolled in the trial, randomized 2:1 to receive ACP-01 or a placebo, will have completed the last follow-up appointments by March 31, 2021. The Company will provide additional information once trial data has been analyzed.
Jan 22, 2021 09:15 am ET
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
Calgary, Alberta--(Newsfile Corp. - January 22, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) ("Hemostemix" or the "Company") is pleased to announce it has signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development. An initiative to assist high-potential, biotech focused Canadian Small and Medium Enterprise (SMEs), the program is designed to accelerate the growth of Hemostemix and other Canadian biotechnology companies.
Jan 04, 2021 08:00 am ET
Hemostemix Announces Grant of Stock Options
Calgary, Alberta--(Newsfile Corp. - January 4, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that, in accordance with its stock option plan, it has granted on December 31, 2020, subject to regulatory approval, a total of 5,274,500 stock options to purchase common shares of ‎Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted 3,887,100 vest immediately and 1,387,400 vest 50% immediately and 50% on December, 31 2021. All options were granted with an exercise price of $0.70 per common share and have an expiry date of December 31, 2025. After ‎this Option issuance, Hemostemix has 5,342,000 Options issued and outstanding.
Dec 31, 2020 09:06 am ET
Hemostemix Announces Closing of Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - December 31, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") announced on December 18, 2020, for gross proceeds of $2,750,000 (the "Offering"). The Offering consisted of the issuance of an aggregate of 9,166,667 post -consolidated Units at a price of $0.30 per Unit. Each Unit consists of one post-consolidated common share in the capital of the Company ("Common Share") and one post-consolidated common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $1.00 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Dec 29, 2020 09:35 am ET
Hemostemix Announces Private Placement Update
Calgary, Alberta--(Newsfile Corp. - December 29, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that it was granted price protection of its previously announced non-brokered private placement of units ("Units") announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of one post rollback common share in the capital of the Company ("Common Share") and one post rollback common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $1.00 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Dec 23, 2020 11:05 pm ET
Hemostemix Announces Corporate Update
Calgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed consolidation of the common shares of the Company on the basis of twenty pre-consolidation shares for one post-consolidation share (the "Consolidation") will take effect, subject to final acceptance by the TSX Venture Exchange, on or about December 30, 2020 under new CUSIP number 423694306.
Dec 18, 2020 04:01 pm ET
Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement
Calgary, Alberta--(Newsfile Corp. - December 18, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $1,272,117.04 (the "Offering"). The Offering consisted of the issuance of an aggregate of 127,211,704 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.05 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Jul 13, 2020 08:25 am ET
Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020
Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the quarter ending March 31, 2020 and for the comparable period ending March 31, 2019.
Jul 10, 2020 08:59 pm ET
Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019
Calgary, Alberta--(Newsfile Corp. - July 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its audited Financial Statements and Management Discussion and Analysis for the annual period and fourth quarter ending December 31, 2019 and for the comparable periods ending December 31, 2018.
Jul 09, 2020 07:00 pm ET
Hemostemix Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - July 9, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $266,500
Jul 06, 2020 05:47 pm ET
Delaware Court Grants An Order for the Expedited Briefing Schedule of Hemostemix's Injunction against Accudata Solutions, Inc. and Hemostemix is in Receipt of an Unsigned Report from Aspire Health Sci
Calgary, Alberta--(Newsfile Corp. - July 6, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that the United States District Court for the District of Delaware has granted an order for the expedited briefing schedule on Hemostemix's Injunction application seeking the immediate return of all clinical trial data from Accudata Solutions, Inc. ("Accudata"). The Order directs Defendant Accudata to file an Answering Brief in response to Hemostemix's Motion for Preliminary Injunction on or before July 9, 2020. The Hemostemix Reply Brief in support of its Motion for Preliminary Injunction shall be filed on or before July 13, 2020. The Court scheduled a hearing on the preliminary injunction motion for July 15, 2020 at 8:30 a.m. ET.
Jul 03, 2020 09:15 am ET
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data
Calgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce on June 29, 2020, it filed a Verified Complaint and, on July 2, 2020, Motions for a Preliminary Injunction and Expedited Scheduling seeking to compel the immediate return of all clinical trial data from Defendant Accudata Solutions, Inc. ("Accudata") and enjoining Accudata from continuing to divulge and disclose such highly sensitive and confidential information to third parties who have no ownership or custodial right to it.
Jun 24, 2020 08:39 pm ET
Hemostemix Appeals Alberta Court's Service Ex Juris Decision
Calgary, Alberta--(Newsfile Corp. - June 24, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that, further to its June 19, 2020 news release, Hemostemix has filed a fast track appeal in relation to the Alberta Court of Queen's Bench erroneous service ex juris decision rendered on June 18, 2020 in relation to Hemostemix's Replevin application seeking access to and a copy of Hemostemix's own property which is being wrongfully withheld from Hemostemix by Aspire Health Science, LLC. In addition, Hemostemix announces that on June 19, 2020, the Court issued supplemental reasons, reversing a key portion of the Court's previous decision issued a day earlier on the Replevin application. Hemostemix believes its appeal raises meritorious issues of error of the Court.
Jun 19, 2020 09:34 am ET
Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC
Calgary, Alberta--(Newsfile Corp. - June 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company")  is pleased to announce a non-brokered private placement of units ("Units") for gross proceeds of up to $700,000 (the "Offering"), subject to TSX Venture Exchange (the "Exchange") approval. The Offering may consist of the issuance of an aggregate of 70,000,000 Units at a price of $0.01 per Unit. Each Unit consists of one Common Share in the capital of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.05 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described as follows. If on any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date of the Offering the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange Inc. ("Exchange") is greater than $0.07 per Common Share, the Company may provide notice in writing to the holders of the Warrants by issuance of a press release that the expiry date of the Warrants will be accelerated to the 30th day after the date on which the Company issues such press release. The proceeds from the Offering are expected to pay finder fees payable in connection with the closing ($56,000), filing fees and legal fees in connection with the litigation against Aspire Health Science, LLC ($350,000), clinical trial costs accounts payable ($250,000) and general working capital ($44,000).
Jun 16, 2020 01:23 pm ET
Hemostemix Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order
Calgary, Alberta--(Newsfile Corp. - June 16, 2020) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM) (OTC: HMTXF) announces, that it has not met the revised filing date, as ‎provided in Alberta Blanket Order 51-517 Temporary Exemption from Certain ‎Corporate Finance Requirements (the "Alberta Order") of the Alberta Securities ‎Commission (and similar exemptions ‎provided by the securities commission in British ‎Columbia)‎ of June 15, 2020, for filing of the following continuous disclosure documents (collectively, the "Documents"):
Jun 08, 2020 01:15 pm ET
Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix's Intellectual Property
Calgary, Alberta--(Newsfile Corp. - June 8, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that ownership and control of its intellectual property is an uncontested fact, and the Company is in communication with each clinical trial site. The Company has lawfully and properly cancelled certain license rights to Aspire Health Science, LLC ("Aspire").
Jun 03, 2020 10:09 am ET
Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial Manager
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Mary Argent-Katwala to the position of Manager, Clinical Trials.
Jun 03, 2020 09:44 am ET
Hemostemix Announces Injunction Hearing Against Aspire Health Science, LLC
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that it has retained DLA Piper, a global law firm, and filed for an injunction against Aspire Health Science, LLC, for the return of the Company's property. A hearing for the injunction is set for June 18, 2020 at 10:00 MDT before the Court of Queen's Bench, Alberta. Equally, the Company is pleased to announce DLA Piper filed an amended motion to dismiss the Aspire Health Science, LLC Complaint in the Complex Business Litigation Court of the Ninth Judicial Circuit, in and for Orange County, Florida.
May 07, 2020 09:15 am ET
Hemostemix Announces Annual Special Meeting Results
Calgary, Alberta--(Newsfile Corp. - May 7, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces the Company completed its Annual Special Meeting of Shareholders on May 6, 2020. All motions put forward by management were approved by Shareholders, including the consolidation of the common shares on a one (1) new share for each 20 shares issued. The vote results are detailed in the attached table.
May 07, 2020 09:10 am ET
Hemostemix Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 7, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF)  ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $1,291,500 (the "Offering"). The Offering consisted of the issuance of an aggregate of 129,150,000 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.05 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Apr 30, 2020 09:15 am ET
Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors
Calgary, Alberta--(Newsfile Corp. - April 30, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of David H. Tsubouchi, B.A., J.D., LL.D., D.S.Litt., C.Dir. to its Board of Advisors.
Apr 29, 2020 09:15 am ET
Hemostemix Announces Private Placement and Debt Settlement Update
Calgary, Alberta--(Newsfile Corp. - April 29, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that, subject to TSX Venture Exchange ("TSXV") approval, its non-brokered private placement will be increased from $450,000 to $1,223,200 of units (the "Units") at $0.01 per Unit (the "Offering"), and the settlement ("Debt Settlement") of trade payables will amount up to $358,514 at $0.01 per common share.
Apr 21, 2020 12:20 pm ET
Hemostemix Announces the Appointment of Timothy Chang to Board of Advisors
Calgary, Alberta--(Newsfile Corp. - April 21, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Timothy C. Chang to its Board of Advisors.
Apr 09, 2020 09:15 am ET
Hemostemix Announces the Appointments of Loran Swanberg and Christina Wu, CPA, CGA
Calgary, Alberta--(Newsfile Corp. - April 9, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Loran Swanberg to its Board of Directors. Mr. Swanberg is a successful businessman who increased his ownership of the Company from 0.8% in 2019 to 7.8% in 2020. In combination with Mssrs. Lacey, Hershman and Smeenk, the board now owns 21% of the Company's shares.
Apr 07, 2020 09:15 am ET
Hemostemix Appoints the Honourable Sheila Copps, OC, PC, to Board of Advisors and Ratifies Thomas Smeenk as Chief Executive Officer
Calgary, Alberta--(Newsfile Corp. - April 7, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of the Honorable Sheila Copps, OC, PC, to its Board of Advisors. Sheila was the Deputy Prime Minister of Canada, Minister of Environment, Minister of Heritage and a senior member of the federal cabinet for 10 years. From her work on diversity and inclusion, to protection of the environment, to support for young Canadians and women, Sheila has had a storied career that has left an indelible mark on Canadian public policy.
Mar 26, 2020 08:00 pm ET
Hemostemix Announces Closing of Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - March 26, 2020) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM) (OTC: HMTXF) announces it has closed the second tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of up to $3,000,000 (the "Offering"). The second tranche of the Offering consisted of the issuance of an aggregate of 17,750,000 Units at a price of $0.01 per Unit for gross proceeds of $177,500. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.05 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Mar 19, 2020 09:00 am ET
Hemostemix Announces Peter Lacey as Chairman of the Board of Directors
Calgary, Alberta--(Newsfile Corp. - March 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the election of Mr. Peter Lacey, ICD.D as Chairman of its Board of Directors.
Mar 16, 2020 09:00 am ET
Hemostemix Announces Dr. York Hsiang Joins Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - March 16, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of York N. Hsiang, MB. ChB, MHSc, FRCSC, Professor of Vascular Surgery at the University of British Columbia, and Consultant Surgeon at the Vancouver General Hospital, to its Scientific Advisory Board ("SAB").
Mar 10, 2020 09:09 pm ET
Hemostemix Announces Corporate Update
Calgary, Alberta--(Newsfile Corp. - March 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has paid $2,330,633.84 to counsel for J.M. Wood Investments Ltd,("JM Wood") in full satisfaction of the Court of Queen's Bench of Alberta Order dated February 28, 2020. JM Wood's application for the appointment of a receiver is now dismissed. Pursuant to the Order, the Company paid into trust with counsel for JM Wood, on March 9, 2020, the aggregate amount of $2,330,633.84 including additional interest and recoverable costs claimed by JM Wood accrued from February 20, 2020 through to March 9, 2020 (the "Secured Amount"). In accordance with the Order, counsel for JM Wood consented to the discharge and release of the security granted to JM Wood by the Company pursuant to each of the Debenture GSA and the Loan Agreement GSA and any other security granted to JM Wood by the Company in relation to the Loan Agreement or the Debenture.
Mar 05, 2020 04:05 pm ET
Hemostemix Announces Closing of First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - March 5, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed the initial tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of up to $3,000,000 (the "Offering"). The first tranche of the Offering consisted of the issuance of an aggregate of 254,620,442 Units at a price of $0.01 per Unit for gross proceeds of $2,546,204.42. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.05 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below. A total of 31,172,320 of the Units issued concurrently with the closing of the Offering were issued to three directors of the Company on the same terms as the Offering.
Mar 02, 2020 07:57 am ET
IIROC Trading Resumption - HEM
VANCOUVER, March 2, 2020 /CNW/ - Trading resumes in:
Feb 28, 2020 06:28 pm ET
Hemostemix Announces Corporate Update
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) announces the Court of Queen’s Bench of Alberta (the “Court”) issued an order dated February 28, 2020 (the “Order”) dismissing J.M. Wood Investments Ltd.’s (“JM Wood”)...
Feb 28, 2020 07:10 am ET
IIROC Trading Halt - HEM
VANCOUVER, Feb. 28, 2020 /CNW/ - The following issues have been halted by IIROC:
Feb 27, 2020 09:15 am ET
Hemostemix Announces Corporate Update
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) provides the following update: Further to the Company’s press release dated February 25, 2020, the Company confirms it will be appearing in the Court Queen’s Bench of...
Feb 25, 2020 09:30 am ET
Hemostemix Announces Corporate Update
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) provides the following update: On February 21, 2020, the Court Queen’s Bench of Alberta (the “Court”), after having heard the concerns raised by the Company with respect to...
Feb 19, 2020 08:00 pm ET
Hemostemix Announces Financing Update and Secured Convertible Debenture Financing of Up to $2,000,000
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce that it is proceeding with its non-brokered private placement of units, as announced January 2, 2020 (the “Unit Offering”). In addition, the Company...
Feb 10, 2020 09:03 am ET
Hemostemix Announces the Appointment of Dr. Ronnie Hershman to the Board of Directors and Provides a Corporate Update
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Dr. Ronnie Hershman, M.D., F.C.C.S., to its Board of Directors. Dr. Hershman is a successful, practicing cardiologist with over three...
Jan 26, 2020 11:00 pm ET
Hemostemix Provides Corporate Update and Clarification
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) provides the following corporate update and clarification of previous disclosure. Retraction: The Company hereby retracts disclosure made by the Company in its January 2020...
Jan 02, 2020 08:30 am ET
Hemostemix Announces Private Placement
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:  HEM; OTC: HMTXF), announces the Company will proceed with a non-brokered private placement of up to 300,000,000 units (the “Units”) at $0.01 per Unit for gross proceeds of up to...
Dec 11, 2019 07:30 am ET
Hemostemix Announces Corporate Update
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTC: HMTXF) is pleased to announce the appointment of David Wood to the position of Chairman, Bryson Goodwin to the position of Chief Executive Officer, Thomas Smeenk to the...
Dec 03, 2019 03:15 pm ET
IIROC Trading Resumption - HEM
VANCOUVER, Dec. 3, 2019 /CNW/ - Trading resumes in:
Dec 02, 2019 10:38 pm ET
Hemostemix Announces Appointment of Director and Postponement of Annual and Special Meeting
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTC: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Nov 29, 2019 02:04 pm ET
Hemostemix Announces Appointment of Director
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Nov 22, 2019 04:30 pm ET
Hemostemix Announces Director Resignation
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Nov 22, 2019 03:42 pm ET
IIROC Trading Halt - HEM
VANCOUVER, Nov. 22, 2019 /CNW/ - The following issues have been halted by IIROC:
Nov 19, 2019 08:30 am ET
Hemostemix Provides Corporate Update
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, announces that the Company and Kingsman...
Oct 31, 2019 08:30 am ET
Hemostemix Provides Corporate Update
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), is a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, announces that it has conducted a...
Oct 21, 2019 08:30 am ET
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is pleased to provide a summary of the...
Oct 17, 2019 07:30 am ET
Hemostemix Announces Commencement of Arbitration
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Aug 01, 2019 08:30 am ET
Hemostemix Announces $2 Million Loan Facility
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Jul 11, 2019 08:30 am ET
Hemostemix Announces Financing Update and Interim CFO Appointment
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Jul 02, 2019 08:30 am ET
Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is pleased to announce that it’s abstract was...
Jun 27, 2019 08:30 am ET
Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has enrolled a total of forty (40) patients in its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”) to-date.  As...
Jun 25, 2019 08:30 am ET
Hemostemix Announces Resignation of CFO
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
May 16, 2019 08:30 am ET
Hemostemix Closes First Tranche of Financing
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
May 03, 2019 08:30 am ET
Hemostemix Announces Convertible Debenture Financing
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Apr 15, 2019 08:30 am ET
Hemostemix Announces Convertible Debenture Financing
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Apr 09, 2019 08:30 am ET
Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has reached an enrollment milestone in its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”).  Enrollment rates...
Apr 01, 2019 08:30 am ET
Hemostemix Announces Appointment of Experienced Chief Medical Officer & President
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D, Ph.D. has been appointed the Company’s President and Chief Medical Officer.  Dr. Jacobs previously acted...
Feb 25, 2019 08:30 am ET
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC Davis Health (“UC Davis”) located in Sacramento, California to be the clinical trial site for the...
Feb 04, 2019 08:30 am ET
Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by...
Jan 17, 2019 08:30 am ET
Hemostemix Provides Highlights of 2018 Accomplishments
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on accomplishments and milestones that it has achieved in 2018.  The past twelve months has seen a transformation...
Jan 03, 2019 08:00 am ET
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical...
Nov 09, 2018 08:30 am ET
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and development activities.  Further to the Company’s press release dated November 8, 2018 where it...
Nov 08, 2018 08:30 am ET
Hemostemix Announces Important Manufacturing Process Refinements
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its manufacturing process, which will result in an approximate 40% reduction in manufacturing time for its...
Nov 07, 2018 08:30 am ET
Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from three new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb...
Oct 30, 2018 09:07 am ET
Hemostemix Announces OTCQB Listing and DTC Eligibility
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce the Company has been approved for up-listing its common shares for trading on the OTCQB Venture Market, a US trading platform that is operated...
Oct 09, 2018 08:30 am ET
Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from three new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb...
Sep 27, 2018 08:30 am ET
Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that at the Annual and Special Meeting of Shareholders (the "Meeting") held on September 26, 2018, shareholders overwhelmingly approved all the resolutions...
Sep 24, 2018 08:30 am ET
Hemostemix Announces Addition to Its Clinical Trial Management Team
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that Catherine St. George has joined the Company as a Clinical Trial Manager.  Ms. St. George has over 20 years of clinical research experience in phase II...
Aug 16, 2018 08:30 am ET
Hemostemix Announces Two New Strategic Trial Sites in Texas
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from two significant institutions to be clinical trial sites for the Company’s Phase II clinical trial for critical limb...
Jul 18, 2018 08:30 am ET
Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated three additional patients including its first two patients in the United States under its continuing Phase II Clinical Trial for critical...
Jul 05, 2018 08:30 am ET
Hemostemix Formalizes World-Class Scientific Advisory Board
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board (“SAB”).   Members of the SAB are all leaders in their fields of expertise, which span biochemistry, molecular...
May 30, 2018 08:30 am ET
Hemostemix Announces Major Milestone Achieved With First 3 U.S. Trial Sites for Phase II Clinical Trial Open for Patient Enrollment
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has entered into agreements and has received all approvals from three additional facilities that have agreed to be clinical trial sites for the...
May 23, 2018 08:30 am ET
Hemostemix Announces New EU Patent Grant
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has been granted a new patent in the European Union (the “EU”) for its patent entitled “Regulating Stem Cells”.  The EU Patent and Trademark Office...
May 03, 2018 08:30 am ET
Hemostemix Announces First Patient Treated in Phase II Clinical Trial
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”).  The first patient was treated at the...
Apr 27, 2018 08:30 am ET
Hemostemix Announces Trial Site for Phase II Clinical Trial
CALGARY, Alberta, April 27, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has entered into an agreement and has received all approvals from the Vancouver Coastal Health Research...
Apr 19, 2018 08:30 am ET
Hemostemix Announces US FDA Clinical Trial Approval
NOT FOR DISSEMINATON TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Feb 26, 2018 08:00 am ET
Hemostemix Signs License Agreement with Aspire Health Science
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Feb 23, 2018 08:00 am ET
Hemostemix Signs License Agreement with Aspire Health Science
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Feb 22, 2018 08:00 am ET
Hemostemix Signs Manufacturing Agreement with Aspire Health Science
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Dec 20, 2017 07:30 am ET
Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Nov 30, 2017 11:17 am ET
Hemostemix Drives Forward with Talented New Management into New Headquarters
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Sep 26, 2017 08:00 am ET
Hemostemix Announces Agreement with CRO Service Provider Topstone Research
BLACKFALDS, Alberta, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce it has engaged Topstone Research Inc. (“Topstone”) to provide clinical research monitoring services, project management, regulatory document management, and related services to advance the Company’s international, multicenter, Phase II clinical trial for patients with critical limb ischemia (CLI). Topstone, is a Toronto, Ontario based global full-service contract research organization (“CRO”) service provider....
Sep 19, 2017 08:28 pm ET
Acquisition and Disposition of Securities of Hemostemix Inc.
Wood Capital Ltd. ("Wood Capital") an entity controlled by Blake Wood, acquired 88,000,000 units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE: HEM), with each Unit consisting of one common share (a "Share") of the Issuer and one-half Share purchase warrant (a "Warrant"), with each whole Warrant entitling the holder to acquire one additional Share for CDN$0.20 for a period of 2 years from the issuance of the Warrants, with an accelerated exercise provision attached to each Warrant commencing on the day following (x) the issuance of
Sep 19, 2017 08:28 pm ET
Acquisition and Disposition of Securities of Hemostemix Inc.
Wood Capital Ltd. ("Wood Capital") an entity controlled by Blake Wood, acquired 88,000,000 units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE:HEM), with each Unit consisting of one common share (a "Share") of the Issuer and one-half...
Aug 25, 2017 06:06 pm ET
Hemostemix Completes Private Placement and Rights Offering
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
Aug 15, 2017 09:26 pm ET
Hemostemix Announces Updates on Private Placement
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) announced today that the Company and PI Financial Corp. (the "Agent") have mutually...
Aug 15, 2017 09:24 pm ET
Hemostemix Announces Updates on Rights Offering
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) is pleased to announce that the Company has raised gross proceeds of $1,063,750.75 from...
Jul 21, 2017 07:53 pm ET
Hemostemix Announces Updates on Rights Offering and Private Placement
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) is pleased to announce that today it mailed and filed the definitive materials related...
Jul 11, 2017 06:47 pm ET
Hemostemix Announces Engagement of PI Financial Corp., Rights Offering and Updates on Proposed Private Placement and Senior Secured Credit Financing
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) is pleased to announce that it has entered into an agreement with PI Financial Corp....
Jun 30, 2017 04:14 pm ET
Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE: HEM) today announces that at the Annual and Special Meeting of Shareholders (the "Meeting") held on June 29, 2017, shareholders overwhelmingly approved (i) fixing the number of directors on the Company's board of directors (the "Board") at three, (ii) electing three directors, namely Angus H. Jenkins, David L. Wood and Donald E. Friesen to the Board, (iii) the re-appointment of MNP LLP, Chartered Accountants, as auditors, (iv) the re-approval of Hemostemix's rolling stock option plan and (v)
Jun 30, 2017 04:14 pm ET
Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) today announces that at the Annual and Special Meeting of Shareholders (the "Meeting") held on June 29, 2017, shareholders overwhelmingly approved (i) fixing the number of...
Jun 09, 2017 07:58 am ET
Hemostemix Inc. Announces Update on Status of Agreement with Hemostemix (Asia) Corporation (HEMA)
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) today announced that it has determined to reinstate the agreement between the Company...
Apr 10, 2017 08:28 am ET
Hemostemix Announces CDN$4,400,000 Senior Secured Debt Financing and Plans to Undertake a Private Placement for up to CDN$8,000,000
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) is pleased to announce that an agreement has been reached with Wood Capital Ltd. ("Wood...
Mar 22, 2017 08:28 am ET
Hemostemix Announces Corporate Updates
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) announces additional progress and details of the corporate reorganization of the...
Feb 09, 2017 04:22 pm ET
IIROC Trading Resumption - HEM; DYU.H; HSI
VANCOUVER, Feb. 9, 2017 /CNW/ - Trading resumes in:
Feb 08, 2017 08:37 pm ET
Hemostemix Announces Further Progress and the Resumption of Trading
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) (OTCQX:HMTXF) announces additional progress and details of the corporate reorganization...
Jan 25, 2017 04:50 pm ET
Acquisition and Disposition of Securities of Hemostemix Inc.
Wood Capital Ltd. ("Wood Capital") an entity controlled by Blake Wood, acquired a CDN$1,000,000 convertible debenture (the "Debenture"). The Debenture is convertible into units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE:HEM) at a...
Jan 25, 2017 04:50 pm ET
Acquisition and Disposition of Securities of Hemostemix Inc.
Wood Capital Ltd. ("Wood Capital") an entity controlled by Blake Wood, acquired a CDN$1,000,000 convertible debenture (the "Debenture"). The Debenture is convertible into units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE: HEM) at a conversion price of CDN$0.16 per Unit. Each Unit consists of one common share (a "Share") of the Issuer and one-half Share purchase warrant (a "Warrant"), with each whole Warrant entitling the holder to acquire one additional Share for CDN$0.30 within 36 months of the original issuance of the
Jan 25, 2017 04:22 pm ET
Acquisition and Disposition of Securities of Hemostemix Inc.
Drive Capital Corp. ("Drive Capital") an entity controlled by Jed M. Wood, acquired a CDN$1,000,000 convertible debenture (the "Debenture"). The Debenture is convertible into units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE: HEM) at a conversion price of CDN$0.16 per Unit. Each Unit consists of one common share (a "Share") of the Issuer and one-half Share purchase warrant (a "Warrant"), with each whole Warrant entitling the holder to acquire one additional Share for CDN$0.30 within 36 months of the original issuance of
Jan 25, 2017 04:22 pm ET
Acquisition and Disposition of Securities of Hemostemix Inc.
Drive Capital Corp. ("Drive Capital") an entity controlled by Jed M. Wood, acquired a CDN$1,000,000 convertible debenture (the "Debenture"). The Debenture is convertible into units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE:HEM) at a...
Jan 25, 2017 01:28 pm ET
Hemostemix Announces Reorganization
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM) announces additional progress and details of the corporate reorganization of the Company...